A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial ...

Ron Lanton, partner, Lanton Law, explains why evolving federal guidance and new technologies are pushing clinical operations teams to strengthen oversight and safeguard the credibility of clinical ...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 ...

Selected patients with a clinical response after therapy could benefit from salvage surgery in non–small cell lung cancer (NSCLC), with acceptable results for perioperative morbidity.

Q2 2025 Earnings Call Transcript August 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.28. Operator: Hello, and thank you for standing ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3 ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

Two new potential drugs have been designed by AI to kill drug-resistant bacteria, in a major Massachusetts Institute of ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second ...

Discover MiNK Therapeutics' Q2 2025 earnings call highlights: major clinical milestones, groundbreaking trials, funding updates, and a focus on ...

A survey published in the Journal of Medical Ethics looks at electroconvulsive therapy (ECT) and what information recipients recall being given. Prof Declan McLoughlin, Research Professor of ...